Latest Bayer Yakuhin Ltd. Stories

TARRYTOWN, N.Y., Sept. 28, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that EYLEA(®) (aflibercept) Injection has received approval for the treatment of patients with neovascular age-related macular degeneration (wet AMD) from the Japanese Ministry of Health, Labour and Welfare (MHLW). In Japan, EYLEA treatment is initiated with one 2 milligram (mg) intravitreal injection per month for three consecutive months (treatment initiation)....

TARRYTOWN, N.Y., May 8, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Bayer HealthCare today announced that Bayer's Japanese subsidiary, Bayer Yakuhin, Ltd. ("Bayer Yakuhin"), and Santen Pharmaceutical Co., Ltd.?"Santen"?entered into a co-promotion agreement for EYLEA® (aflibercept) Injection in Japan. As previously announced, Bayer Yakuhin has submitted an application for marketing authorization to the Ministry of Health, Labor and Welfare (MHLW) for...

ATLANTA, March 22, 2012 /PRNewswire/ -- Femasys Inc., an emerging medical device developer of women's healthcare solutions, today announced an agreement with Bayer Yakuhin, Ltd., Osaka, Japan, for exclusive distribution rights in Japan for Femasys' FemVue(TM) Saline-Air Device. This is the first device that allows physicians to quickly and effectively evaluate with ultrasound a woman's fallopian tubes, a critical component of her fertility assessment. The FemVue evaluation...

TARRYTOWN, N.Y. and BERLIN, June 28, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that Bayer Yakuhin, Ltd., Osaka, Japan, has submitted an application to the Ministry of Health, Labor and Welfare (MHLW) in Japan for marketing authorization for EYLEA(TM), also known as VEGF Trap-Eye, for the treatment of the neovascular form of age-related macular degeneration (wet AMD). Regeneron and Bayer HealthCare are collaborating on the...